S. Sumitran-Karuppan

Pre- and post-transplant sensitization in cyclosporin A-treated patients

E. Möller, A. Lindholm, S. Sumitran-Karuppan, 1988 .

CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients.

P. Ljungman, C. Söderberg, S. Sumitran-Karuppan, 1996, Transplantation.

SPECIFIC INHIBITION OF HLA CLASS I AND II ANTIBODIES BY SOLUBLE ANTIGENS—A METHOD FOR THE IDENTIFICATION OF ANTIBODY SPECIFICITY IN SERA FROM ALLOIMMUNIZED INDIVIDUALS

E. Möller, E. Möller, S. Sumitran-Karuppan, 1994, Transplantation.

The use of magnetic beads coated with soluble HLA class I or class II proteins in antibody screening and for specificity determinations of donor-reactive antibodies.

S. Sumitran-Karuppan, E. Moller, 1996, Transplantation.

Cytomegalovirus-induced CD13-specific autoimmunity--a possible cause of chronic graft-vs-host disease.

P. Ljungman, S. Larsson, B. Rozell, 1996, Transplantation.

Antibodies in alloimmunized uraemic patients treated with recombinant erythropoietin

I. Fehrman‐Ekholm, S. Sumitran-Karuppan, 1994, Transplant international : official journal of the European Society for Organ Transplantation.

The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies.

S. Sumitran-Karuppan, S. Sumitran-karuppan, 1999, Transplantation.

Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells.

F. Reinholt, U. Berg, G. Tydén, 1997, Transplant immunology.

Acid treatment of lymphocytes selectively decreases the expression of HLA class I antigens: a method to confirm that a positive clinical crossmatch test was due to class I antibodies.

E. Möller, S. Sumitran-Karuppan, 1996, Transplant immunology.

Role of alloimmunity in clinical transplantation.

C. Söderberg-Nauclér, E. Möller, S. Sumitran-Karuppan, 1999, Reviews in immunogenetics.